Angst und Depressivität bei Tumorpatienten im Verlauf der radioonkologischen Behandlung

Maurer, Julia; Schäfer, C.; Maurer, Odilo; Kölbl, Oliver

doi:10.1007/s00066-012-0143-y

Cited by 15 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depression can have a negative impact on memory performance [37,38] and is frequent in patients treated with radiotherapy [39]. In order to account for effects of depression on the primary outcome variable, the German version of the Hospital Anxiety and Depression Scale (HADS-D) [40] is used.…”

Section: Assessment Of Depressionmentioning

confidence: 99%

Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) – a phase II prospective randomized multicenter trial (NOA-14, ARO 2015–3, DKTK-ROG)

et al. 2020

View full text Add to dashboard Cite

Background: Whole brain radiation therapy (WBRT) is the standard therapy for multiple brain metastases. However, WBRT has a poor local tumor control and is associated with a decline in neurocognitive function (NCF). Aim of this trial is to assess the efficacy and safety of a new treatment method, the WBRT with hippocampus avoidance (HA) combined with the simultaneous integrated boost (SIB) on metastases/resection cavities (HA-WBRT+SIB). Methods: This is a prospective, randomized, two-arm phase II multicenter trial comparing the impact of HA on NCF after HA-WBRT+SIB versus WBRT+SIB in patients with multiple brain metastases. The study design is double-blinded. One hundred thirty two patients are to be randomized with a 1:1 allocation ratio. Patients between 18 and 80 years old are recruited, with at least 4 brain metastases of solid tumors and at least one, but not exceeding 10 metastases ≥5 mm. Patients must be in good physical condition and have no metastases/resection cavities in or within 7 mm of the hippocampus. Patients with dementia, meningeal disease, cerebral lymphomas, germ cell tumors, or small cell carcinomas are excluded. Previous irradiation and resection of metastases, as well as the number and size of metastases to be boosted have to comply with certain restrictions. Patients are randomized between the two treatment arms: HA-WBRT+SIB and WBRT+SIB. WBRT is to be performed with 30 Gy in 12 daily fractions and the SIB with 51 Gy/42 Gy in 12 daily fractions on 95% of volume for metastases/resection cavities. In the experimental arm, the dose to the hippocampi is restricted to 9 Gy in 98% of the volume and 17Gy in 2% of the volume. NCF testing is scheduled before WBRT, after 3 (primary endpoint), 9, 18 months and yearly thereafter. Clinical and imaging

show abstract

Section: Assessment Of Depressionmentioning

confidence: 99%

Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) – a phase II prospective randomized multicenter trial (NOA-14, ARO 2015–3, DKTK-ROG)

et al. 2020

View full text Add to dashboard Cite

show abstract

Measuring psychosocial functioning in the radiation oncology clinic: a systematic review

Hess

Chen

2014

Psycho-Oncology

View full text Add to dashboard Cite

show abstract

Physical and psychosocial support requirements of 1,500 patients starting radiotherapy

et al. 2013

View full text Add to dashboard Cite

show abstract

Angst und Depressivität bei Tumorpatienten im Verlauf der radioonkologischen Behandlung

Abstract: More than one third of the treated patients suffered from positive or marginally positive symptoms of anxiety and depression. This present study showed a decrease of anxiety and depression symptoms during the course of radiotherapy.

Cited by 15 publications

References 24 publications

Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) – a phase II prospective randomized multicenter trial (NOA-14, ARO 2015–3, DKTK-ROG)

Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) – a phase II prospective randomized multicenter trial (NOA-14, ARO 2015–3, DKTK-ROG)

Measuring psychosocial functioning in the radiation oncology clinic: a systematic review

Physical and psychosocial support requirements of 1,500 patients starting radiotherapy

Contact Info

Product

Resources

About